StockData
Korro Bio, Inc. logo

Korro Bio, Inc. (KRRO) stock

KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$12.32−0.39 (-3.07%)

Close on Nov 17, 2026Market cap $181.42MP/E –Yield –

Korro Bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Korro Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$67.95M. For fiscal 2025 it was -$78.56M. The highest annual figure on record is $34.22M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$78.56M–
FY2024Dec 31, 2024-$60.07M–
FY2023Dec 31, 2023-$67.28M–
FY2022Dec 31, 2022-$53.65M–
FY2021Dec 31, 2021-$76.06M–
FY2020Dec 31, 2020-$45.19M-232.1%
FY2019Dec 31, 2019$34.22M–
FY2018Dec 31, 2018-$17.02M–
FY2017Dec 31, 2017-$14.61M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$16.99M–
Q1 FY2026Mar 31, 2026-$16.07M–
Q4 FY2025Dec 31, 2025-$17.70M–
Q3 FY2025Sep 30, 2025-$17.18M–
Q2 FY2025Jun 30, 2025-$19.23M–
Q1 FY2025Mar 31, 2025-$24.45M–
Q4 FY2024Dec 31, 2024-$7.50M–
Q3 FY2024Sep 30, 2024-$16.10M–
Q2 FY2024Jun 30, 2024-$14.59M–
Q1 FY2024Mar 31, 2024-$21.89M–
Q4 FY2023Dec 31, 2023-$21.11M–
Q3 FY2023Sep 30, 2023-$11.77M–
Q2 FY2023Jun 30, 2023-$14.72M–
Q1 FY2023Mar 31, 2023-$19.69M–
Q4 FY2022Dec 31, 2022-$11.03M–
Q3 FY2022Sep 30, 2022-$11.80M–
Q2 FY2022Jun 30, 2022-$13.48M–
Q1 FY2022Mar 31, 2022-$17.34M–
Q4 FY2021Dec 31, 2021-$17.89M–
Q3 FY2021Sep 30, 2021-$15.02M–
Q2 FY2021Jun 30, 2021-$17.67M–
Q1 FY2021Mar 31, 2021-$25.47M–
Q4 FY2020Dec 31, 2020-$14.83M–
Q3 FY2020Sep 30, 2020-$10.73M-114.4%
Q2 FY2020Jun 30, 2020-$10.26M–
Q1 FY2020Mar 31, 2020-$9.36M–
Q4 FY2019Dec 31, 2019-$29.74M–
Q3 FY2019Sep 30, 2019$74.58M–
Q2 FY2019Jun 30, 2019-$4.47M–
Q1 FY2019Mar 31, 2019-$6.15M–
Q4 FY2018Dec 31, 2018-$4.72M–

More Korro Bio figures

See a number that looks wrong?